

## Article

# Synthesis of Some New 1,3,4-Thiadiazole, Thiazole and Pyridine Derivatives Containing 1,2,3-Triazole Moiety

Nadia A. Abdelriheem, Ali M. M. Mohamed and Abdou O. Abdelhamid \*

Department of Chemistry, Faculty of Science, Cairo University, Giza 12613, Egypt;  
Nadia.abdelhamid5@gmail.com (N.A.A.); Ali.egypt3@gmail.com (A.M.M.M.)

\* Correspondence: Abdelhamid45@gmail.com; Tel.: +20-010-0520-5750

Academic Editor: Panayiotis A. Koutentis

Received: 13 December 2016; Accepted: 7 February 2017; Published: 10 February 2017

**Abstract:** In this study, 1-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethan-1-one, was reacted with Thiosemicarbazide, alkyl carbodithioate and benzaldehyde to give thiosemicarbazone, alkylidenhydrazinecarbodithioate and 3-phenylprop-2-en-1-one-1,2,3-triazole derivatives. The 1,3,4-thiadiazole derivatives containing the 1,2,3-triazole moiety were obtained via reaction of alkylidenecarbodithioate with hydrazonoyl halides. Also, hydrazonoyl halides were reacted with thiosemicarbazone and pyrazolylthioamide to give 1,3-thiazoles derivatives. Subsequently, 3-phenyl-2-en-1-one was used to synthesize substituted pyridines and substituted nicotinic acid ester. The latter was converted to its azide compound which was reacted with aromatic amines and phenol to give substituted urea and phenylcarbamate containing 1,2,3-triazole moiety. The newly synthesized compounds were established by elemental analysis, spectral data and alternative synthesis whenever possible.

**Keywords:** 1,3,4-thiadiazoles; 1,2,3-triazoles; hydrazonoyl halides; pyridines; nicotinic ester


## 1. Introduction

In synthesis, 1,2,3-triazoles are useful building blocks and are additionally important due to their broad range of biological activities [1,2]—they are stable to moisture, oxygen, light and metabolic process. A series of novel 1,2,3-triazoles were synthesized [3] and found to have cytotoxic activity against human cancer cell lines such as U937, THP-1, HL60 and B16-F10. The 1,3,4-thiadiazole ring is one of the most important and well-known heterocyclic nuclei, as a common and integral feature of a variety of natural products and medicinal agents. As a core structural component, 1,2,4-thiadiazole is present in an array of drug categories such as antimicrobial, anti-inflammatory, analgesic, antiepileptic, antiviral, antineoplastic, antitubercular and antinociceptive agents [4,5]. Thiazoles display a broad range of biological activities and are found in many potent biologically active molecules such as antimicrobial, antifungal and antineoplastic drugs [6]. However, they are mostly known for their anticancer [7] and antimicrobial [8] activities. Also, pyridine derivatives, including those bearing various heterocyclic nuclei, have shown potent pharmacological properties, including antifungal [9,10], antitubercular [11], antimalarial [12], antibacterial [13], antimicrobial [14], or insecticide [15]. We report here the synthesis of new 1,3,4-thiadiazoles, 5-arylazothiazoles, and pyridines containing 1,2,3-triazole moiety.

## 2. Results

Treatment of 1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethan-1-one (1) [16] with methyl or benzyl carbodithioate [16,17] in 2-propanol gave the corresponding methyls 2-(1-(5-methyl-1-(*p*-tolyl)-1*H*-

1,2,3-triazol-4-yl)ethylidene)hydrazinecarbodithioate (**2a**) [17] and benzyl 2-(1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinecarbodithioate (**2b**) [18], respectively (Scheme 1). Structures **2a** and **2b** were elucidated by elemental analyses, spectral data and chemical transformation. Thus, treatment of **2a** or **2b** with ethyl 2-chloro-2-(2-phenylhydrazono)acetate (**3a**) in ethanolic triethylamine at room temperature gave one isolated product formulated as ethyl 5-((1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)-hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (**7a**) (Scheme 1). The latter was confirmed by elemental analysis, spectral data, and an alternative synthesis route. Thus, ethyl 5-hydrazono-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (**8**) [19] was reacted with compound **1**, in 2-propanol to give a product identical in all aspects (m.p., mixed m.p., and spectra) with **7a**.




**Scheme 1.** Synthesis of 1,3,4-thiadiazoles **7a,b**.

In light of these results, the mechanism outlined in Scheme 1 seems to be the most plausible pathway for the formation of **7a** from the reaction of the **2a** (or **2b**) with **3a**. The reaction involves initial formation of thiohydrazonate **5**, which undergoes intermolecular cyclization as soon as it is formed to yield the intermediate **6** or via 1,3-dipolar cycloaddition of nitrilimine **4a** (generated in situ from **3a** with triethylamine) to the C=S double bond of **2**. The formations of **5** and **6** are similar to the reactions of hydrazonoyl halides with 1-phenyl-1,4-dihydro-1,3,4-thiadiazole-5-thione [20] and 5-phenyl-1,3,4-thiadiazole-2(3*H*)-thione [21]. Intermediate **6** was converted to **7** by elimination of methanthiol (or benzylthiol). Analogously, treatment of the appropriate **2a** (or **2b**) with **3b** gave 2,3-dihydro-1,3,4-thiadiazoles **7b**, in good yield (Scheme 1).

After 2-(1-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinecarbothioamide (**9**) [21] was reacted with hydrazonoyl chloride **3c** in ethanolic triethylamine under reflux to give the

corresponding 2-(2-(1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)-hydrazinyl)-4-phenyl-5-(phenyldiazenyl)thiazole (**11b**) in quantitative yield (Scheme 2), structure **11b** was confirmed by elemental analysis, spectral data and alternative synthesis. Thus, 2-(2-(1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)-hydrazinyl)-4-phenylthiazole (**12**) [22], prepared from reaction of **1** with 2-hydrazinyl-4-phenylthiazole (**13**) [23], or reaction of **9** with  $\omega$ -bromoacetophenone [21], was coupled with benzenediazonium chloride in ethanolic sodium acetate at 0–5 °C to furnish a product identical in all aspects (m.p., mixed m.p., and spectra) to **11b**. Analogously, treatment of **9** with the appropriate **3b,d,e** gave thiazole derivatives **11a,c,d** respectively, in good yields (Scheme 2).





**Scheme 2.** Synthesis of thiazoles **11a–d**.

A similar treatment of **9** with ethyl 2-chloro-2-(2-phenylhydrazono)acetate (**3a**) in ethanolic triethylamine gave 2-(2-(1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)-hydrazinyl)-5-(2-phenylhydrazono)thiazol-4(5*H*)-one (**14a**) (Scheme 3). Structure **14a** was elucidated by elemental analysis, spectral data and an alternative synthetic route. Thus, treatment of benzenediazonium chloride with 2-(2-(1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)-hydrazinyl)thiazol-4(5*H*)-one (**15**), prepared via reaction of **9** with ethyl chloroacetate in boiling ethanol, in a cold ethanolic sodium acetate solution, afforded a product identical in all aspects (m.p., mixed m.p., and spectra) with **14a**.

Analogously, the appropriate arenediazonium chloride was coupled with **15** in ethanolic sodium acetate afforded (2-(2-(1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)-hydrazinyl)-5-(2-aryldiazeno)thiazol-4(5*H*)-one **14b** and **14c**; respectively (Scheme 3). Also, compound **15** was reacted with benzaldehyde in ethanol in the presence of a catalytic amount of piperidine, giving 5-(benzylidene)-2-(2-(1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)-hydrazinyl)thiazol-4(5*H*)-one (**16**).

Treatment of 3-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazole-1-carbothioamide (**17**) [24,25] with the appropriate  $\alpha$ -keto-hydrazoneyl halides **3a,c,e,f** in ethanolic triethylamine afforded 5-(aryldiazenyl)-4-substituted-2-(3-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-5-(aryldiazenyl)-4-substituted thiazole **20a–d**, respectively (Scheme 4). Structures **20a–d** were elucidated via elemental analyses, spectral data and alternative synthetic routes. Thus, 2-(3-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-4-phenylthiazole (**21**) was coupled with benzenediazonium chloride in ethanolic sodium acetate solution at 0–5 °C, affording a product identical in all aspects (m.p., mixed m.p., and spectra) with **20b**.



R = 5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl

i = EtOH, Et<sub>3</sub>N/ 80° C

3 a, R' = CH<sub>3</sub>, Ar = C<sub>6</sub>H<sub>5</sub>

c, R' = C<sub>6</sub>H<sub>5</sub>, Ar = C<sub>6</sub>H<sub>5</sub>

e, R' = CH<sub>3</sub>, Ar = 4-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>


f, R' = C H<sub>3</sub>, Ar = 4-ClC<sub>6</sub>H<sub>4</sub>

**Scheme 4.** The 2-(3-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-5-(aryldiazenyl)-4-substituted thiazole **20a–d**.

In the light of these results, the mechanism outlined in Scheme 4 seems to be the most plausible pathway for the formation of **20** from the reaction of **17** with **3**. The reaction involves initial formation of thiohydrazone **18**, which undergoes cyclization as soon as it is formed to yield the intermediate **19**. The latter suffers dehydration to the final product **20**.

Treatment of **17** with **3b** in ethanolic triethylamine gave 2-(3-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-5-(2-phenylhydrazono)thiazol-4(5*H*)-one (**22**) in a good yield. Structure **22** was confirmed by elemental analysis and spectral data.

Next, treatment of compound **23** with each of ethyl acetoacetate, acetylacetone, malononitrile, ethyl cyanoacetate, cyanothioacetamide and benzoylacetonitrile in acetic acid containing ammonium acetate afforded pyridine derivatives **24–29**, respectively (Scheme 5). Structures **24–29** were elucidated on the basis of elemental analysis, spectral data and chemical transformation (cf. Experimental and Scheme 5). <sup>1</sup>H-NMR spectrum of **24** showed signals at  $\delta$  = 1.34 (t, 3H, CH<sub>3</sub>CH<sub>2</sub>O), 2.4 (s, 3H, 4-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>), 2.60 (s, 3H, CH<sub>3</sub>, pyridine H-2), 2.69 (s, 3H, CH<sub>3</sub>, triazole H-5), 4.2 (q, 2H, CH<sub>3</sub>CH<sub>2</sub>O), 7.27–7.73 (m, 9H, ArH's), 7.90 (s, 1H, pyridine H-5).



**Scheme 5.** Synthesis of substituted pyridine derivatives **24–29**.


Thus, treatment of **24** with hydrazine hydrate in boiling ethanol gave 2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylnicotinohydrazide (**31**) in a good yield. Structure **31** was elucidated via elemental analyses, spectral data and chemical transformation. Compound **31** was reacted with each of acetylacetone, ethyl acetoacetate, or with sodium nitrite in the presence of acetic acid to give **32**, **33** and azido **34**, respectively (Scheme 6).

Meanwhile, each of the compounds **32** and **33** were reacted with benzenediazonium chloride in ethanolic sodium acetate solution, giving (3,5-dimethyl-4-(phenyldiazenyl)-1*H*-pyrazol-1-yl)-(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylpyridin-3-yl)methanone (**35a**) and 5-methyl-2-[2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-[1,2,3]triazol-4-yl)-4-phenylpyridine-3-carbonyl]-4-(phenylhydrazono)-2,4-dihydro-pyrazol-3-one (**36a**) (Scheme 6). The structure of compounds **35a** and **36a** were confirmed by alternative synthesis, by treatment of the hydrazide **31** with each of 3-(2-

phenylhydrazono)pentane-2,4-dione (**37a**) [26] and ethyl 3-oxo-2-(phenylhydrazono)butanoate (**37b**) [27] in boiling acetic acid for products identical in all aspects (m.p., mixed m.p., and spectra) with **35a** and **36a**, respectively.

Analogously, *p*-tolyldiazonium chloride was reacted with each **32** and **33**, giving (3,5-dimethyl-4-(*p*-tolyldiazenyl)-1*H*-pyrazol-1-yl)(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylpyridin-3-yl)methanone (**35b**) and 5-methyl-2-(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylpyridin-3-yl)-4-(2-(*p*-tolyl)-hydrazono)-2,4-dihydro-3*H*-pyrazol-3-one (**36b**), respectively (Scheme 6).

Azido(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylpyridin-3-yl)methanone (**34**) can be converted into urea derivatives, **38a,b** and 3-(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylpyridin-3-yl)quinazoline-2,4(1*H*,3*H*)-dione (**39**) by being boiled with the appropriate aromatic amines, or anthranilic acid in dry dioxane, respectively. Also, phenyl 2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylpyridin-3-ylcarbamate **40** can be obtained by boiling the azido **34** with phenol in dry benzene (Scheme 6).



Scheme 6. Synthesis of pyrazoles, urea, quinazoline and carbamate.

### 3.1. Materials and Methods

All meeting points were determined on an electro thermal Gallen Kamp melting point apparatus (Laim George, Calgary, AB, Canada) and are uncorrected. IR ( $\text{cm}^{-1}$ ) spectra were recorded on KBr disk on a FTIR-8201 spectrophotometer (Shimadzu, Tokyo, Japan).  $^1\text{H}$ -NMR and  $^{13}\text{C}$ -NMR spectra were measured in deuterated dimethyl sulfoxide ( $\text{DMSO}-d_6$ ) using a Varian Gemini 300 NMR spectrometer

(Varian, Inc., Karlsruhe, Germany). Mass spectra were recorded on a Shimadzu GCMS-QP1000 EX mass spectrometer (Tokyo, Japan) at 70 eV. Measurements of the elemental analysis were carried out at the Microanalytical Centre of Cairo University, Giza, Egypt. All reactions were followed by TLC (Silica gel, Merck, Kenilworth, NJ, USA). Hydrazonoyl halides were prepared as previously reported [28–31]

### 3.1.1. Alkyl 2-(1-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-ethylidene)hydrazine-1-carbodithioate **2a** and **2b**

A mixture of 1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethanone (**1**) [16] (1 g, 5 mmol) and alkyl carbodithioate (5 mmol) in 2-propanol (20 mL) was refluxed for 30 min. The reaction mixture was cooled and the resulting solid was collected and crystallized from the proper solvent to give **2a,b**.

*Methyl 2-(1-(5-methyl-1-(p-tolyl)-1H-1,2,3-triazol-4-yl)-ethylidene)hydrazine-1-carbodithioate (2a)*. Buff crystals from ethanol: yield: 75%, m.p.: 186 °C, FT-IR (KBr, cm<sup>-1</sup>): 3522 (NH), 3064 (CH), 1603 (C=N), 1561 (C=C); <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.36 (s, 3H, CH<sub>3</sub>), 2.45 (s, 3H, CH<sub>3</sub>), 2.50 (s, 3H, CH<sub>3</sub>), 3.20 (s, 3H, CH<sub>3</sub>), 7.38–7.51 (m, 4H, ArH's) and 12.4 (s, br, 1H, NH). Anal. Calcd. For C<sub>14</sub>H<sub>17</sub>N<sub>5</sub>S<sub>2</sub> (319.46) C, 52.64; H, 5.36; N, 21.92; S, 20.07 Found C, 52.70; H, 5.40; N, 21.90; S, 20.18.

*Benzyl 2-(1-(5-methyl-1-(p-tolyl)-1H-1,2,3-triazol-4-yl)-ethylidene)hydrazine-1-carbodithioate (2b)*. Buff crystals from DMF: yield 75%, m.p.: 324 °C, FT-IR (KBr, cm<sup>-1</sup>): 3421 (NH), 3052 (CH), 1611 (C=N), 1553 (C=C); <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.41 (s, 3H, CH<sub>3</sub>), 2.50 (s, 3H, CH<sub>3</sub>), 2.73 (s, 3H, CH<sub>3</sub>), 3.28 (s, 2H, CH<sub>2</sub>), 7.39–7.47 (m, 9H, ArH's) and 12.35 (s, br, 1H, NH). Anal. Calcd. For C<sub>20</sub>H<sub>21</sub>N<sub>5</sub>S<sub>2</sub> (395.54) C, 60.73; H, 5.35; N, 17.71; S, 16.21 Found C, 60.69; H, 5.32; N, 17.68; S, 16.30.

### 3.1.2. 5-((1-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-derivatives **7a,b**

**Method A:** Triethyl amine (0.75 mL, 0.5 g, 5 mmol) was added dropwise with stirring to a mixture of the appropriate alkyl carbodithioate **2a** or **2b** (5 mmol) and the appropriate hydrazonoyl halides **3a,b** [27–30] (5 mmol) in ethanol (20 mL). The resulting solid which formed after 30 min was collected and crystallized from the proper solvent to give the corresponding thiadiazole derivatives **7a,b**.

*Ethyl 5-((1-(5-methyl-1-(p-tolyl)-1H-1,2,3-triazol-4-yl)ethylidene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (7a)*. Yellow crystals from acetic acid Yield: 70%, m.p.: 205–207 °C; FT-IR (KBr, cm<sup>-1</sup>): 3047 (CH), 1708 (CO), 1616 (C=N), 1573 (C=C); <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ = 1.59 (t, 3H, CH<sub>2</sub>-CH<sub>3</sub>), 2.48 (s, 3H, CH<sub>3</sub>), 2.64 (s, 3H, CH<sub>3</sub>), 2.71 (s, 3H, CH<sub>3</sub>), 4.50 (q, 2H, CH<sub>2</sub>-CH<sub>3</sub>), and 7.26–8.18 (m, 9H, ArH's); MS (EI, *m/z* (%)): 461 (M<sup>+</sup>, 100), 433 (20), 400 (80), 289 (20), 243 (20), 184 (30), 91 (30), 80 (100), 64 (40); Anal. Calcd. For C<sub>23</sub>H<sub>23</sub>N<sub>7</sub>SO<sub>2</sub> (461.55), C, 59.85; H, 5.02; N, 21.24; S, 6.95 Found C, 59.90; H, 5.12; N, 21.34; S, 6.99

*1(5-((1-(5-Methyl-1-(p-tolyl)-1H-1,2,3-triazol-4-yl)ethylidene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)ethan-1-one (7b)*. Yellow crystals from ethanol. Yield: 80%, m.p.: 270–271 °C; FT-IR (KBr, cm<sup>-1</sup>): 2924 (CH), 1678 (CO), 1616 (C=N), 1573 (C=C); <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ = 2.48 (s, 3H, CH<sub>3</sub>), 2.63 (s, 3H, CH<sub>3</sub>), 2.65 (s, 3H, CH<sub>3</sub>), 2.71 (s, 3H, CH<sub>3</sub>), and 7.26–8.14 (m, 9H, ArH's); <sup>13</sup>C-NMR in CHCl<sub>3</sub> δ = 9.4 (5-CH<sub>3</sub> triazole), 13.9 (=CH<sub>3</sub>), 19.9 (4-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>), 24.7 (CH<sub>3</sub>CO), 123.3, 125.4, 127.2, 127.8, 129.3, 130.2, 132.4, 139.7, 140.7, 142.33, 147.8, 152.7, 163.8, 189.1 (CO), MS (EI, *m/z* (%)): 431 (M<sup>+</sup>, 100), 403 (5), 370 (10), 360 (30), 301 (10), 259 (15), 194 (55), 184 (3), 172 (40), 91 (50), 80 (100), 64 (50); Anal. Calcd. For C<sub>22</sub>H<sub>21</sub>N<sub>7</sub>OS (431.52), C, 61.23; H, 4.91; N, 22.72; S, 7.43 Found C, 61.40; H, 4.89; N, 22.80; S, 7.80

Alternative synthesis of Ethyl 5-(1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (**7a**).

**Method B:** A mixture of ethyl 5-hydrazono-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (**8**) [18] (1.3 g, 5 mmol) and 1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethanone (**1**) (1 g, 5 mmol) in 2-propanol were heated for 30 min. The crude solid that was collected and crystallized from ethanol gave a product identical in all aspects (m.p., mixed m.p. and spectra) with **7a**.

### 3.1.3. 2-(2-(1-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinyl)-thiazole derivatives **11a–d**

**Method A:** A mixture of **9** (1.4 g, 5 mmol), the appropriate hydrazonoyl halides **3b–e** (5 mmol) and triethylamine (0.5 g, 0.7 mL, 5 mmol) in ethanol was heated under reflux for 3 h. The resulting solid that was collected and recrystallized gave thiazole derivatives **11a–d**.

**4-Methyl-2-(2-((*E*)-1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinyl)-5-((*E*)-phenyldiazenyl)thiazole (**11a**).** Orange crystals from acetic acid; Yield: 75%, m.p.: 255 °C; FT-IR (KBr, cm<sup>−1</sup>): 3417 (NH), 3032 (CH), 1600 (C=C); <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ = 2.48 (s, 3H, CH<sub>3</sub>), 2.59 (s, 3H, CH<sub>3</sub>), 2.65 (s, 3H, CH<sub>3</sub>), 3.3 (s, 3H, CH<sub>3</sub>), 6.96–7.55 (m, 9H, ArH's) and 9.18 (s, br, 1H, NH). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ = 8.1, 12.9, 13.7, 20.8, 114.4, 121.6, 123.8, 129.0, 129.6, 129.9, 130.4, 139.1, 139.6, 146.2, 154.6, 160.1, 164.9. Anal. Calcd. For C<sub>22</sub>H<sub>22</sub>N<sub>8</sub>S (430.54): C, 61.37; H, 5.15; N, 26.03; S, 7.4 Found C, 61.40; H, 5.10; N, 26.13; S, 7.50.

**2-(2-((*E*)-1-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinyl)-4-phenyl-5-((*E*)-phenyldiazenyl)thiazole (**11b**).** Orange crystals from ethanol, Yield: 70%, m.p.: 245 °C; FT-IR (KBr, cm<sup>−1</sup>): 3417 (NH), 3074 (CH), 1578 (C=C); <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.45 (s, 3H, CH<sub>3</sub>), 2.49 (s, 3H, CH<sub>3</sub>), 3.30 (s, 3H, CH<sub>3</sub>), 7.32–8.28 (m, 14H, ArH's) and 10.71 (s, br, 1H, NH). Anal. Calcd. For C<sub>27</sub>H<sub>24</sub>N<sub>8</sub>S (492.61): C, 65.83; H, 4.91; N, 22.75; S, 6.51; Found C, 65.79, N, 22.78, S, 6.561.

**4-Methyl-2-(2-((*E*)-1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinyl)-5-((*Z*)-*p*-tolyl diazenyl)thiazole (**11c**).** Gray crystals from acetic acid, Yield: 70%, m.p.: 250 °C; FT-IR (KBr, cm<sup>−1</sup>): 3421 (NH), 3020 (CH), 1593 (C=C); <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.30 (s, 3H, CH<sub>3</sub>), 2.44 (s, 3H, CH<sub>3</sub>), 2.58 (s, 3H, CH<sub>3</sub>), 2.65 (s, 3H, CH<sub>3</sub>), 2.75 (s, 3H, CH<sub>3</sub>), 7.15–7.53 (m, 8H, ArH's), 10.54 (s, br, 1H, NH). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ = 8.1, 12.9, 13.7, 20.8, 21.5, 114.2, 122.0, 123.8, 129.0, 129.6, 129.9, 136.8, 139.4, 139.8, 146.8, 151.6, 156.8, 164.7. Anal. Calcd. For C<sub>23</sub>H<sub>24</sub>N<sub>8</sub>S (444.57), C, 62.14; H, 5.44; N, 25.21; S, 7.21 Found C, 62.15; H, 5.55; N, 25.25; S, 7.30.

**5-((*Z*)-(4-Chlorophenyl)diazenyl)-4-methyl-2-(2-((*E*)-1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinyl)thiazole (**11d**).** Red crystals from ethanol, Yield: 70%, m.p.: 240 °C; FT-IR (KBr, cm<sup>−1</sup>): 3387 (NH), 3089, 3028 (CH), 1585 (C=C); <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.49 (s, 3H, CH<sub>3</sub>), 2.58 (s, 3H, CH<sub>3</sub>), 2.65 (s, 3H, CH<sub>3</sub>), 3.30 (s, 3H, CH<sub>3</sub>), 7.34–7.54 (m, 8H, ArH's) and 10.65 (s, br, 1H, NH). Anal. Calcd. For C<sub>22</sub>H<sub>21</sub>N<sub>8</sub>S (464.99), C, 56.83; H, 4.55; N, 24.10; S, 6.90 Found C, 56.89; H, 4.60; N, 24.15; S, 6.85.

**Method B:** Benzenediazonium chloride (5 mmol), prepared in the usual way from aniline (0.46 g, 5 mmol), hydrochloric acid (1.5 mL, 6 M) and sodium nitrite (0.35 g, 5 mmol), was added dropwise with stirring to a cold solution of 2-(2-(1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinyl)-4-phenylthiazole (**12**) (1.9 g, 5 mmol) and sodium acetate (1.3 g, 10 mmol) in ethanol (30 mL) at 0–5 °C. The reaction mixture was stirred for 3 h in an ice bath and was left in refrigerator overnight. The solid was collected and crystallized from ethanol, giving a product identical (m.p., mixed mp and spectra) with **11b**.

### 3.1.4. 2-(2-(1-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinyl)-4-phenylthiazole (**13**)

**Method A:** A mixture of **9** (1.4 g, 5 mmol) and ω-bromoacetophenone (1 g, 5 mmol) in ethanol was refluxed for 4 h. The resulting solid that was collected and crystallized from ethanol gave a white crystal of **13**, Yield: 75%, m.p. 290 °C (Lit. m.p. 273 °C [22]).

**Method B:** A mixture of 2-hydrazinyl-4-phenylthiazole (**12**) (1.76 g, 10 mmol), **1** (2.1 g, 5 mmol) in ethanol (20 mL) and conc. hydrochloric acid (2 drops) was heated under reflux for 15 min. The solid was collected and crystallized from ethanol giving a product identical in all aspects (m.p., mixed m.p., and spectra) with the above sample obtained by **Method A**.

### 3.1.5. (*E*)-5-(2-Arylhyaazono)-2-((*Z*)-2-(1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)-hydrazinyl)thiazol-4(5*H*)-one **14a–c**

**Method A:** A mixture of **9** (1.4 g, 5 mmol), hydrazonoyl halide **3a** (5mmol) and triethylamine (0.5 g, 0.7 mL, 5 mmol) in ethanol was boiled under reflux for 3 h. The resulting solid was collected and recrystallized from acetic acid afforded by **14a**



**Method B:** Dropwise addition of arenediazonium chlorides (5 mmol), which was prepared via reaction of the appropriate aniline, p-toluidine, p-chloroaniline (5 mmol), hydrochloric acid (1.5 mL, 6 M), sodium nitrite (0.37 g, 5 mmol) at 0–5 °C, to a mixture of **15** (1.64 g, 5 mmol) and sodium acetate (0.66 g, 5 mmol) in ethanol at 0–5 °C, while stirring. The reaction mixture was stirred for 3 h. The resulting solid was collected, washed with water and crystallized, giving **14a–c**.

(*E*)-2-((*Z*)-2-(1-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinyl)-5-(2-phenylhydrazono)thiazol-4(5*H*)-one (**14a**). Yellow crystals from acetic acid, Yield 75%, m.p. 298–300 °C; FT-IR (KBr, cm<sup>−1</sup>): 3431, 3211 (2NH), 3051, 2920 (CH), 1581(C=C), 1659 (CO), 1604 (C=N); <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.44 (s, 3H, CH<sub>3</sub>), 2.49 (s, 3H, CH<sub>3</sub>), 3.32 (s, 3H, CH<sub>3</sub>), 6.92–7.85 (m, 9H, ArH's) 10.5 (s, br, 1H, NH) and 11.9 (s, br, 1H, NH). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ = 8.1, 19.2, 21.0, 115.4, 122.0, 123.8, 127.7, 129.8, 130.1, 139.2, 139.8, 145.7, 146.3, 147.2, 159.4, 167.9, 176.1. Anal. Calcd. For C<sub>21</sub>H<sub>20</sub>N<sub>8</sub>SO (432.51), C, 58.32; H, 4.66; N, 25.91; S, 7.41 Found C, 58.30; H, 4.69; N, 25.80; S, 7.50.

(*E*)-2-((*Z*)-2-(1-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinyl)-5-(2-(*p*-tolyl)hydrazono)thiazol-4(5*H*)-one (**14b**). Brown crystals from ethanol, Yield: 80%, m.p. >300 °C; FT-IR (KBr, cm<sup>−1</sup>): 3437, 3267 (2NH), 2931 (CH), 1732 (CO), 1627 ν(C=N), 1573 ν(C=C). <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.26 (s, 3H, CH<sub>3</sub>), 2.47 (s, 3H, CH<sub>3</sub>), 2.49(s, 3H, CH<sub>3</sub>), 2.53 (s, 3H, CH<sub>3</sub>), 7.41–7.50 (m, 8H, ArH's), 8.41 (s, br, 1H, NH) and 10.9 (s, br, 1H, NH). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ = 8.1, 19.2, 20.6, 21.0, 117.4, 123.9, 128.6, 129.9, 130.2, 136.8, 139.2, 139.8, 145.2, 145.8, 146.3, 159.6, 167.9, 176.0. Anal. Calcd. For C<sub>22</sub>H<sub>22</sub>N<sub>8</sub>OS (446.54), C, 59.18; H, 4.97; N, 25.09; S, 7.18 Found C, 59.28; H, 4.89; N, 25.11; S, 7.28.

(*E*)-5-(2-(4-Chlorophenyl)hydrazono)-2-((*Z*)-2-(1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinyl)thiazol-4(5*H*)-one (**14c**). Pale brown crystals from ethanol, Yield: 70%, m.p.: 263–265 °C; FT-IR (KBr, cm<sup>−1</sup>): 3431, 3108 (2NH), 2972 (CH), 1664 (CO), 1634 (C=N), <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.42 (s, 3H, CH<sub>3</sub>), 2.53 (s, 3H, CH<sub>3</sub>), 3.30 (s, 3H, CH<sub>3</sub>), 7.42–7.51 (m, 8H, ArH's), 8.32 (s, br, 1H, NH) and 11.99 (s, br, 1H, NH). Anal. Calcd. For C<sub>21</sub>H<sub>19</sub>N<sub>8</sub>OSCl (466.96), C, 54.02; H, 4.10; N, 24.00; S, 6.87; Cl, 7.59 Found: C, 54.12; H, 4.20; N, 24.05; S, 6.90.

### 3.1.6. (*E*)-2-(2-(1-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)hydrazinyl)thiazol-4(5*H*)-one (**15**)

A mixture of **9** (1.4 g, 5 mmol) and ethyl chloroacetate (0.61 g, 5 mmol) in ethanol was refluxed for 4 h. The resulting solid was collected and recrystallized from ethanol that gave white crystals of **15**, Yield: 75%, m.p. 255 °C. FT-IR (KBr, cm<sup>−1</sup>): 3116 (NH), 2951 (CH), 1735 (CO), 1624 (C=N). <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.46 (s, 3H, CH<sub>3</sub>), 2.54 (s, 3H, CH<sub>3</sub>), 3.30 (s, 3H, CH<sub>3</sub>), 3.87 (s, 2H, OCH<sub>2</sub>), 7.42–8.32 (m, 4H, ArH's) and 11.97 (s, br, 1H, NH). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ = 8.1, 19.1, 20.8, 37.1, 123.9, 129.7, 129.9, 139.2, 139.7, 146.0, 159.7, 168.0, 183.5. Anal. Calcd. For C<sub>15</sub>H<sub>16</sub>N<sub>6</sub>OS (328.40), C, 54.86; H, 4.91; N, 25.59; S, 9.76 Found: C, 54.90; H, 4.95; N, 25.34; S, 9.70.

### 3.1.7. (*E*)-5-Benzylidene-2-((*E*)-2-(1-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)ethylidene)-hydrazinyl)thiazol-4(5*H*)-one (**16**)

A mixture of **15** (1.6 g, 5 mmol) and benzaldehyde (0.53 g, 5 mmol) in ethanol and catalytic amount of piperidine (5 drops) was refluxed for 3 h. The resulting solid was collected and recrystallized from acetic acid affording white crystals of **16**, Yield: 80%, m.p.: 283 °C. FT-IR (KBr, cm<sup>−1</sup>): 3124 (NH), 2974 (CH), 1705 (CO), 1624 (C=N). <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.49 (s, 3H, CH<sub>3</sub>), 2.54 (s, 3H, CH<sub>3</sub>), 3.30 (s, 3H, CH<sub>3</sub>), 7.42–7.51 (m, 10H, ArH's and =CH) and 11.91 (s, br, 1H, NH). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ = 8.1, 19.1, 20.8, 123.9, 129.2, 129.7, 129.9, 130.7, 132.5, 138.2, 139.3, 139.6, 146.2, 159.8, 167.8, 174.1. Anal. Calcd. For C<sub>22</sub>H<sub>20</sub>N<sub>6</sub>SO (416.51), C, 63.44; H, 4.84; N, 20.18; S, 7.70 Found: C, 63.50; H, 4.90; N, 20.20; S, 7.75.

### 3.1.8. 5-(Aryldiazenyl)-4-substituted-2-(3-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazole-1-yl)thiazole **20a–d**, **21**

**Method A:** A mixture of **17** (1.9 g, 5 mmol), the appropriate hydrazonoyl halides **3a,c,e,f** or **3b** (5 mmol) and triethyl amine (0.5 mg, 0.75 mL, 5 mmol) in ethanol (20 mL) was heated under reflux for 4 h. The resulting solid was collected and recrystallized, giving thiazole derivatives **20a–d** and **21**.

**Method B:** Benzenediazonium chloride (5 mmol) which was prepared via reaction of aniline (0.55 g, 5 mmol), hydrochloric acid (3 mL, 6 M), and sodium nitrite (0.35 g, 5 mmol) was added dropwise, with stirring, to a cold solution of **21**. The reaction mixture was stirred for 3 h. The resulting solid was collected, washed with water and crystallized from ethanol, giving **20b**.

(*E*)-4-Methyl-2-(3-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-5-(phenyldiazenyl)thiazole (**20a**). Orange crystals from acetic acid, Yield: 75%, m.p.: 235 °C; FT-IR (KBr, cm<sup>−1</sup>): 3045, 2926, 2860 (CH), 1653 (C=N), 1587 (C=C); <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.49 (s, 3H, CH<sub>3</sub>), 2.56 (s, 3H, CH<sub>3</sub>), 2.70 (s, 3H, CH<sub>3</sub>), 3.72–3.74 (dd, 1H, H<sub>b</sub>), 3.78 (dd, 1H, H<sub>a</sub>), 5.78 (dd, 1H, H<sub>x</sub>) and 7.26–7.76 (m, 14H, ArH's). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ = 8.1, 12.82, 21.0, 33.2, 63.6, 114.8, 121.7, 123.8, 127.5, 129.1, 129.5, 129.8, 130.1, 130.7, 130.9, 139.2, 139.7, 144.8, 149.6, 154.1, 161.1. MS (EI, *m/z* (%)): 518 (M<sup>+</sup>, 100), 489 (5), 413 (2), 273 (15), 184 (20), 170 (15), 144 (25), 91 (35%), 77 (70), 65 (17). Anal. Calcd. For C<sub>29</sub>H<sub>26</sub>N<sub>8</sub>S (518.65), C, 67.16; H, 5.05; N, 21.61; S, 6.18 Found C, 67.26; H, 5.10; N, 21.69; S, 6.28.

(*E*)-2-(3-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-4-phenyl-5-(phenyldiazenyl)thiazole (**20b**). Red crystals from acetic acid, Yield: 70%, m.p.: 275 °C; FT-IR (KBr, cm<sup>−1</sup>): 3043, 2924 (CH), 1666 (C=N); <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ = 2.49 (s, 3H, CH<sub>3</sub>), 2.71 (s, 3H, CH<sub>3</sub>), 3.73–3.78 (dd, 1H, H<sub>b</sub>), 4.18 (dd, 1H, H<sub>a</sub>), 5.82 (dd, 1H, H<sub>x</sub>), and 7.33–8.18 (m, 19H, ArH's), <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ = 8.1, 12.82, 21.0, 33.2, 63.6, 108.7, 121.7, 123.8, 126.7, 127.4, 128.2, 128.7, 128.2, 129.8, 129.9, 130.1, 130.4, 130.9, 133.1, 136.2, 139.1, 139.7, 144.7, 154.7, 168.0 MS (EI, *m/z* (%)): 580 (M<sup>+</sup>, 85), 551 (30), 447 (10), 367 (30), 133 (40), 91(50), 77(100), 65(20). Anal. Calcd. For C<sub>34</sub>H<sub>28</sub>N<sub>8</sub>S (580.72), C, 70.32; H, 4.86; N, 19.30; S, 5.52 Found C, 70.22; H, 4.75; N, 19.20; S, 5.56.

(*E*)-4-Methyl-2-(3-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-5-(*p*-tolyl-diazenyl)thiazole (**20c**). Red crystals from acetic acid, Yield: 70%, m.p.: 240 °C; FT-IR (KBr, cm<sup>−1</sup>): 3039, 2926 (CH), 1658 (C=N); <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ = 2.40 (s, 3H, CH<sub>3</sub>), 2.46 (s, 3H, CH<sub>3</sub>), 2.60 (s, 3H, CH<sub>3</sub>), 2.72 (s, 3H, CH<sub>3</sub>), 3.5–3.6 (dd, 1H, H<sub>b</sub>), 4.1–4.2 (dd, 1H, H<sub>a</sub>), 5.61–5.64 (dd, 1H, H<sub>x</sub>) and 6.81–8.17 (m, 13H, ArH's). Anal. Calcd. For C<sub>30</sub>H<sub>28</sub>N<sub>8</sub>S (532.68), C, 67.65; H, 5.30; N, 2.04; S, 6.02 Found C, 67.72; H, 5.34; N, 2.14; S, 6.12.

(*E*)-5-((4-Chlorophenyl)diazenyl)-4-methyl-2-(3-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)thiazole (**20d**). Red crystals from ethanol, Yield: 65%, m.p.: 220 °C; FT-IR (KBr, cm<sup>−1</sup>): 3037, 2926 (CH), 1670 (C=N); <sup>1</sup>H-NMR (300 MHz, CDCl<sub>3</sub>): δ = 2.48 (s, 3H, CH<sub>3</sub>), 2.56 (s, 3H, CH<sub>3</sub>), 2.69 (s, 3H, CH<sub>3</sub>), 3.63–3.72 (dd, 1H, H<sub>b</sub>), 4.11–4.21 (dd, 1H, H<sub>a</sub>), 5.64–5.70 (dd, 1H, H<sub>x</sub>) and 6.81–7.71 (m, 13H, ArH's). Anal. Calcd. For C<sub>29</sub>H<sub>25</sub>N<sub>8</sub>SCl (553.09), C, 62.98; H, 4.56; N, 20.26; S, 5.80; Cl, 6.41 Found C, 62.85; H, 4.55; N, 20.30; S, 5.89.

### 3.1.9. 2-(3-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazol-1-yl)-4-phenylthiazole (**21**)

A mixture of **17** (1.85 g, 5 mmol) and ω-bromoacetophenone (1 g, 5 mmol) in ethanol was refluxed for 4 h. The resulting solid was collected and crystallized from ethanol giving white crystals of **21**, Yield: 75%, m.p. 220 °C (Lit. m.p. 193 °C [25]).

### 3.1.10. 2-(3-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-4,5-dihydro-1*H*-pyrazole-1-yl)-5-(2-phenylhydrazono)thiazol-4(5*H*)-one (**22**)

A mixture of 4,5-dihydro-3-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-5-phenyl-pyrazol-1-carbothioamide (**17**) (1.9 g, 5 mmol) and ethyl 2-chloro-2-(2-phenylhydrazono)acetate (**3b**) (1.1 g, 5 mmol) in ethanol (20 mL) was heated under reflux for 3 h. The resulting solid was collected and recrystallized from acetic acid, giving **22** as pale orange crystals. Yield 75%, m.p. 294–296 °C, FT-IR (KBr, cm<sup>−1</sup>): 3437

(NH), 3049, 2929 (CH), 1695 (CO), 1658 (C=N).  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 2.48 (s, 3H,  $\text{CH}_3$ ), 2.65 (s, 3H,  $\text{CH}_3$ ), 3.73–3.85 (dd, 1H,  $\text{H}_b$ ), 4.09–4.19 (dd, 1H,  $\text{H}_a$ ), 5.77–5.81 (dd, 1H,  $\text{H}_x$ ), 7.26–7.38 (m, 15H, ArH's and NH).  $^{13}\text{C-NMR}$  ( $\text{DMSO-}d_6$ )  $\delta$  = 8.1, 12.82, 21.0, 33.2, 67.2, 115.3, 122.3, 123.9, 127.0, 127.8, 128.7, 129.8, 129.9, 130.7, 139.1, 139.7, 144.0, 144.6, 146.7, 149.5, 156.6, 175.1. Anal. Calcd. For  $\text{C}_{28}\text{H}_{24}\text{N}_8\text{OS}$  (520.62): C, 64.60; H, 4.65; N, 21.52; S, 6.16. Found, C, 64.67; H, 4.70; N, 21.60; S, 6.19.

### 3.1.11. 6-(5-Methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylpyridine derivatives 24–29

General procedure: A mixture of **23** (1.5 g, 5 mmol), the appropriate acetylacetone, ethyl acetoacetate, ethyl cyanoacetate, cyanothioacetamide, malononitrile, benzoylacetonitrile and ammonium acetate (0.38 g, 5 mmol) in acetic acid (10 mL) was heated under reflux for 4 h. The resulting solid was filtered, washed with water and crystallized from the proper solvent, giving pyridine derivatives **24–29**.

*Ethyl 2-methyl-6-(5-methyl-1-(p-tolyl)-1H-1,2,3-triazol-4-yl)-4-phenylnicotinate (24)*. Yellow crystals from ethanol, yield 85% m.p.: 195 °C, FT-IR (KBr,  $\text{cm}^{-1}$ ): 3035, 2953 (CH); 1660 (CO), 1629 (C=N); 1579 (C=C);  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 1.34 (t, 3H,  $\text{CH}_2\text{CH}_3$ ), 2.42 (s, 3H,  $\text{CH}_3$ ), 2.60 (s, 3H,  $\text{CH}_3$ ), 2.69 (s, 3H,  $\text{CH}_3$ ), 4.20 (q, 2H,  $\text{CH}_2\text{CH}_3$ ), 7.27–7.73 (m, 10H, ArH's and pyridine H-5).  $^{13}\text{C-NMR}$  ( $\text{DMSO-}d_6$ )  $\delta$  = 11.5, 13.82, 20.9, 23.5, 61.7, 63.6, 93.3, 118.6, 123.0, 125.3, 125.8, 129.4, 129.8, 133.6, 134.52, 142.4, 146.0, 154.3, 167.9, 175. MS (EI,  $m/z$  (%)): 412 ( $\text{M}^+$ , 15), 395 (10), 384 (50), 325 (30), 342 (10), 247 (70), 132 (100), 103 (80), 91 (90), 77 (40), 65 (55). Anal. Calcd. for  $\text{C}_{25}\text{H}_{24}\text{O}_2\text{N}_4$  (412.49), C, 72.80; H, 5.86; N, 13.60. Found: C, 72.86; H, 5.90; N, 13.65.

*1-(2-Methyl-6-(5-methyl-1-(p-tolyl)-1H-1,2,3-triazol-4-yl)-4-phenylpyridin-3-yl)ethan-1-one (25)*. Orange crystals from acetic, yield 70% m.p.: 190 °C, FT-IR (KBr,  $\text{cm}^{-1}$ ): 3002, 2949 (CH); 1737 (CO); 1614 (C=N); 1579 (C=C).  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 2.09 (s, 3H,  $\text{CH}_3$ ), 2.43 (s, 3H,  $\text{CH}_3$ ), 2.46 (s, 3H,  $\text{CH}_3$ ), 2.66 (s, 3H,  $\text{CH}_3$ ) and 7.26–8.14 (m, 10H, ArH's and pyridine H-5), MS (EI,  $m/z$  (%)): 384 ( $\text{M}^+$ , 20), 369 (10), 354 (60), 341 (70), 247 (40), 194 (35), 144 (15), 132 (95), 91 (99), 77 (40), 65 (60). Anal. Calcd. For  $\text{C}_{24}\text{H}_{22}\text{ON}_4$ , (382.47): C, 75.37; H, 5.80; N, 14.65. Found C, 75.47; H, 5.95; N, 14.75.

*2-Amino-6-(5-methyl-1-(p-tolyl)-1H-1,2,3-triazol-4-yl)-4-phenylpyridine-3-carbonitrile (26)*. Yellow crystals from acetic acid, Yield 75%, m.p.: 197 °C, FT-IR (KBr,  $\text{cm}^{-1}$ ): 3427, 3224  $\nu(\text{NH}_2)$ ; 3002, 2954  $\nu(\text{CH})$ ; 2276  $\nu(\text{CN})$ ; 1635  $\nu(\text{C=N})$ ; 1581  $\nu(\text{C=C})$ ,  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 2.46 (s, 3H,  $\text{CH}_3$ ), 2.65 (s, 3H,  $\text{CH}_3$ ), 6.95 (s, br, 2H,  $\text{NH}_2$ ), 7.26–8.14 (m, 10H, ArH's and pyridine H-5).  $^{13}\text{C-NMR}$  ( $\text{DMSO-}d_6$ )  $\delta$  = 11.5, 20.9, 63.6, 91.7, 97.8, 118.4, 118.8, 121.3, 127.5, 128.8, 129.7, 133.52, 133.7, 140.3, 142.5, 150.6, 160.7, 166. MS (EI,  $m/z$  (%)): 366 ( $\text{M}^+$ , 60), 351 (30), 338 (40), 247 (50), 194 (0), 144 (30), 132 (70), 103 (50), 91 (70), 80 (100), 64 (50). Anal. Calcd. for  $\text{C}_{22}\text{H}_{18}\text{N}_6$  (366.43), C, 72.11; H, 4.95; N, 22.94 Found: C, 72.15; H, 4.85; N, 22.88.

*6-(5-Methyl-1-(p-tolyl)-1H-1,2,3-triazol-4-yl)-2-oxo-4-phenyl-pyridine-3-carbonitrile (27)*. Yellow crystals from acetic acid. Yield 75%, m.p. 193 °C, FT-IR (KBr,  $\text{cm}^{-1}$ ): 3433 (NH), 3043, 2929 (CH); 1668 (CO), 1643 (C=N), 1581 (C=C);  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 2.47 (s, 3H,  $\text{CH}_3$ ), 2.65 (s, 3H,  $\text{CH}_3$ ), 7.26–8.14 (m, 10H, ArH's and pyridine H-5), 11.65 (s, br, 1H, NH), MS (EI,  $m/z$  (%)): 368 ( $\text{M}^+$ , 40), 304 (10), 247 (65), 194 (55), 132 (100), 115 (30), 103 (70), 91 (85), 77 (40), 65 (50). Anal. Calcd. For  $\text{C}_{22}\text{H}_{17}\text{N}_5\text{O}$  (367.41), C, 71.92; H, 4.66; N, 19.06 Found: C, 71.89; H, 4.65; N, 19.16.

*6-(5-Methyl-1-(p-tolyl)-1H-1,2,3-triazol-4-yl)-4-phenyl-2-thioxo-pyridine-3-carbonitrile (28)*. Orange crystals from acetic acid, Yield 70%, m.p. 278 °C, FT-IR (KBr,  $\text{cm}^{-1}$ ): 3437 (NH); 3037, 2920 (CH); 2211 (CN), 1584 (C=C), 1615 (C=N),  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 2.41 (s, 3H,  $\text{CH}_3$ ), 2.49 (s, 3H,  $\text{CH}_3$ ), 4.47–8.12 (m, 10H, ArH's, pyridine H-5), 15.45 (s, br, 1H, NH).  $^{13}\text{C-NMR}$  ( $\text{DMSO-}d_6$ )  $\delta$  = 8.5, 20.9, 108.4, 112.2, 118.3, 123.2, 128.8, 129.7, 129.9, 130.4, 135.4, 135.8, 137.4, 139.4, 139.8, 150.3, 150.7, 177.8. MS (EI,  $m/z$  (%)): 383 ( $\text{M}^+$ , 40), 303 (5), 247 (50), 194 (50), 132 (100), 103 (60), 90 (100), 77 (50), 68 (60). Anal. Calcd. For  $\text{C}_{22}\text{H}_{17}\text{N}_5\text{S}$  (383.48), C, 68.91; H, 4.47; N, 18.26; S, 8.36. Found C, 68.89; H, 4.37; N, 18.30 S, 8.46.

*(2-Amino-6-(5-methyl-1-(p-tolyl)-1H-1,2,3-triazol-4-yl)-4-phenylpyridin-3-yl)(phenyl)-methanone (29)*. Pale yellow crystals from ethanol, Yield 70%, m.p.: 183 °C, FT-IR (KBr,  $\text{cm}^{-1}$ ): 3431, 3330 ( $\text{NH}_2$ ); 2972, 2925 (CH), 1659 (CO); 1596 (C=C).  $^1\text{H-NMR}$  (300 MHz,  $\text{CDCl}_3$ ):  $\delta$  = 2.49 (s, 3H,  $\text{CH}_3$ ), 2.56 (s, 3H,  $\text{CH}_3$ ), 6.93

(s, br, 2H, NH<sub>2</sub>), 7.26–8.12 (m, 15H, ArH's and pyridine H-5). Anal. Calcd. For C<sub>28</sub>H<sub>23</sub>N<sub>5</sub>O (445.53), C, 75.49; H, 5.20; N, 15.72 Found C, 75.39; H, 5.40; N, 15.65.

### 3.1.12. 2-Methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylnicotinohydrazide (**31**)

Equimolar amounts of ethyl 6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenyl pyridine-3-carboxylate (**24**) (2.2 g, 5 mmol) and hydrazine hydrate (1 mL, 10 mmol) in ethanol (10 mL) were refluxed for 5 h. The resulting solid was collected and recrystallized, giving **31** as white crystals from ethanol, Yield 89%, m.p. 145 °C, FT-IR (KBr, cm<sup>-1</sup>): 3431, 3335 (NH<sub>2</sub>); 2960, 2923 (CH); 1662 (CO); 1572 (C=C). <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.24 (s, br, 2H, NH<sub>2</sub>), 2.42 (s, 3H, CH<sub>3</sub>), 2.60 (s, 3H, CH<sub>3</sub>), 2.97 (s, 3H, CH<sub>3</sub>), 10.20 (s, br, 1H, NH), 7.11–7.61 (m, 10H, ArH's and pyridine H-5). Anal. Calcd. For C<sub>23</sub>H<sub>22</sub>N<sub>6</sub>O (398.42): C, 69.33; H, 5.57; N, 21.09 Found C, 69.35; H, 5.60; N, 21.19.

### 3.1.13. (3,5-Dimethyl-1*H*-pyrazol-1-yl)(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenyl-pyridin-3-yl)methanone (**32**) and 5-Methyl-2-(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenyl-pyridine-3-carbonyl)-2,4-dihydropyrazol-3-one (**33**)

Equimolar amounts of **31** and the appropriate acetylacetone or ethyl acetoacetate (4 mmol for each) in ethanol (10 mL), with two drops of acetic acid, were refluxed for 4 h. The resulting solid was collected and recrystallized from ethanol, giving the corresponding products **32** and **33**, respectively.

(3,5-Dimethyl-1*H*-pyrazol-1-yl)(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenyl-pyridin-3-yl) methanone (**32**). White crystals from ethanol, Yield 80%, m.p. 207 °C, FT-IR (KBr, cm<sup>-1</sup>): 3032, 2961, 2941, 2839 (CH); 1641 (CO); 1589 (C=C). <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.41 (s, 3H, CH<sub>3</sub>), 2.48 (s, 3H, CH<sub>3</sub>), 2.49 (s, 3H, CH<sub>3</sub>), 2.57 (s, 3H, CH<sub>3</sub>), 2.70 (s, 3H, CH<sub>3</sub>), 7.21–7.57 (m, 11H, ArH's, pyridine H-5 and pyrazole H-4). Anal. Calcd. For C<sub>28</sub>H<sub>26</sub>N<sub>6</sub>O (462.56): C, 72.71; H, 5.67; N, 18.17 Found C, 72.80; H, 5.81; N, 18.27.

5-Methyl-2-(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenyl-pyridine-3-carbonyl)-2,4-dihydropyrazol-3-one (**33**). White crystals from ethanol, Yield 80%, m.p. 217 °C, FT-IR (KBr, cm<sup>-1</sup>): 3434 (OH); 2976, 2925 ν(CH); 1682 (CO); 1609 (C=N), 1575 (C=C). <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.21 (s, 3H, CH<sub>3</sub>), 2.48 (s, 3H, CH<sub>3</sub>), 2.57 (s, 3H, CH<sub>3</sub>), 2.62 (s, 3H, CH<sub>3</sub>), 4.67 (s, 2H, pyrazoline H-4), 7.19–7.52 (m, 10H, ArH's, pyridine H-5). Anal. Calcd. For C<sub>27</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub> (464.53): C, 69.81; H, 5.21; N, 18.09 Found C, 69.91; H, 5.33; N, 18.19.

### 3.1.14. Azido (2-Methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenyl-pyridin-3-yl)-methanone (**34**)

To a stirred solution of **31** (5 mmol) in acetic acid (15 mL) at 0–5 °C, sodium nitrite was added portion-wise until effervescence ended. The reaction mixture was stirred for 1 h. The resulting solid was collected, filtered, washed with water and recrystallized, giving the azido derivative **34**. Buff crystals from acetic acid, yield (86%) m.p. 160 °C, FT-IR (KBr, cm<sup>-1</sup>): 2964, 2924 (CH); 1641 (CO), 1609 (C=C). <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.44 (s, 3H, CH<sub>3</sub>), 2.50 (s, 3H, CH<sub>3</sub>), 2.69 (s, 3H, CH<sub>3</sub>), 7.17–7.57 (m, 10H, ArH's and pyridine H-5). Anal. Calcd. For C<sub>23</sub>H<sub>19</sub>N<sub>7</sub>O (409.49): C, 67.47; H, 4.68; N, 23.95 Found C, 67.50; H, 4.70; N, 23.99.

### 3.1.15. 4-(Aryldiazenyl-3,5-dimethylpyrazol-1-yl)(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenyl-pyridin-3-yl)methanone (**35a,35b**) and 4-(Arylhydrazono)-5-methyl-2-(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenyl-pyridin-3-carbonyl)-2,4-dihydropyrazol-3-one (**36a, 36b**)

Dropwise addition of the appropriate arenediazonium chloride (5 mmol), which was prepared via reaction of appropriate aniline or *p*-toluidine (5 mmol), hydrochloric acid (1.5 mL, 6M) and sodium nitrite (0.37 g, 5 mmol) at 0–5 °C, to a mixture of the appropriate **32** or **33** (5 mmol) and sodium acetate (1.3 g, 5 mmol) in ethanol (30 mL) at 0–5 °C while stirring the reaction mixture was stirred for

3 h. The resulting solid was collected, washed with water and recrystallized from acetic acid, giving **35a**, **35b**, **36a** and **36b**, respectively.

(*E*)-(3,5-Dimethyl-4-(phenyldiazenyl)-1*H*-pyrazol-1-yl)(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylpyridin-3-yl)methanone (**35a**). Orange crystals from acetic acid, Yield 70%, m.p. 170 °C, FT-IR (KBr, cm<sup>-1</sup>): 2925 (CH); 1722 (CO); 1608 (C=N), 1566 (C=C); <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.28 (s, 3H, CH<sub>3</sub>) 2.44 (s, 3H, CH<sub>3</sub>), 2.50 (s, 3H, CH<sub>3</sub>), 2.60 (s, 3H, CH<sub>3</sub>), 2.69 (s, 3H, CH<sub>3</sub>) and 7.17–7.97 (m, 15H, ArH's, pyridine H-5). Anal. Calcd. For C<sub>34</sub>H<sub>30</sub>N<sub>8</sub>O (566.67): C, 72.07; H, 5.34; N, 19.77 Found C, 72.16; H, 5.29; N, 19.88

(*E*)-(3,5-Dimethyl-4-(*p*-tolyl-diazenyl)-1*H*-pyrazol-1-yl)(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylpyridin-3-yl)methanone (**35b**). Orange crystals from acetic acid, Yield 70%, m.p. 175 °C, FT-IR (KBr, cm<sup>-1</sup>): 2966, 2924 (CH); 1722 (CO); 1647 (C=N); 1605 (C=C). <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.25 (s, 3H, CH<sub>3</sub>) 2.44 (s, 3H, CH<sub>3</sub>), 2.49 (s, 3H, CH<sub>3</sub>), 2.50 (s, 3H, CH<sub>3</sub>), 2.69 (s, 3H, CH<sub>3</sub>), 2.71 (s, 3H, CH<sub>3</sub>) and 7.17–7.98 (m, 14H, ArH's, pyridine H-5). Anal. Calcd. For C<sub>35</sub>H<sub>32</sub>N<sub>8</sub>O (580.70): C, 72.39; H, 5.55; N, 19.30 Found C, 72.49; H, 5.66; N, 19.40.

(*E*)-5-Methyl-2-(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylnicotinoyl)-4-(phenyldiazenyl)-2,4-dihydro-3*H*-pyrazol-3-one (**36a**). Orange crystals from acetic acid, Yield 70%, m.p. 165 °C, FT-IR (KBr, cm<sup>-1</sup>): 3432 (OH); 2975, 2921 (CH); 1721 (CO); 1679 (C=N); 1584 (C=C). <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.31 (s, 3H, CH<sub>3</sub>) 2.43 (s, 3H, CH<sub>3</sub>), 2.58 (s, 3H, CH<sub>3</sub>), 2.69 (s, 3H, CH<sub>3</sub>), 4.35 (s, br, 1H, pyrazoline), 7.09–7.58 (m, 15H, ArH's and pyridine H-5). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ = 9.6, 11.8, 20.8, 24.4, 115.3, 123.4, 125.7, 126.8, 128.4, 129.7, 130.4, 132.4, 133.3, 138.8, 139.5, 139.8, 140.8, 169.0, 171.2, 172.5, 170.0. Anal. Calcd. For C<sub>33</sub>H<sub>28</sub>N<sub>8</sub>O<sub>2</sub> (568.64): C, 69.70; H, 4.96; N, 19.71 Found C, 69.65; H, 4.85; N, 19.72.

(*E*)-5-Methyl-2-(2-methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylnicotinoyl)-4-(*p*-tolyl-diazenyl)-2,4-dihydro-3*H*-pyrazol-3-one (**36b**). Orange crystals from acetic acid, Yield 70%, m.p. 170 °C, FT-IR (KBr, cm<sup>-1</sup>): 2974, 2922 (CH); 1721 (C=O); 1649 (C=N); 1608 (C=C). <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.42 (s, 3H, CH<sub>3</sub>), 4.50 (s, 1H, pyrazoline), 2.49 (s, 3H, CH<sub>3</sub>), 2.57 (s, 3H, CH<sub>3</sub>), 2.69 (s, 3H, CH<sub>3</sub>), 2.71 (s, 3H, CH<sub>3</sub>), and 7.14–7.57 (m, 14H, ArH's and pyridine H-5). Anal. Calcd. For C<sub>34</sub>H<sub>30</sub>N<sub>8</sub>O<sub>2</sub> (582.67): C, 70.09; H, 5.19; N, 19.23 Found C, 70.19; H, 5.20; N, 19.10.

3.1.16. 1-(2-Methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenyl-pyridin-3-yl)-3-substituted urea (**38a**, **38b**) and 3-(2-Methyl-6-(methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenyl-pyridin-3-yl)quinazoline-2,4-(1*H*,3*H*)dione (**39**)

A mixture of **34** (2 g, 5mmol) and appropriate aniline, *p*-toluidine, anthranilic acid (or methyl anthranilate) (5 mmol) in dry dioxane (20 mL) was refluxed for 4 h. The resulting solid that was collected and recrystallized from the proper solvent gave **38a**, **38b** and **39**, respectively

1-(2-Methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylpyridin-3-yl)-3-phenylurea (**38a**). White crystals from acetic acid yield 70%, m.p. 180 °C. FT-IR (KBr, cm<sup>-1</sup>): 3426 (NH); 2983, 2926 (CH); 1722 (CO); 1647 (C=N); 1594 (C=C). <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.43 (s, 3H, CH<sub>3</sub>) 2.59 (s, 3H, CH<sub>3</sub>), 2.71 (s, 3H, CH<sub>3</sub>), 7.44–7.97 (m, 15H, ArH's and pyridine H-5), 8.88 (s, br, 2H, 2NH). Anal. Calcd. For C<sub>29</sub>H<sub>26</sub>N<sub>6</sub>O (474.57): C, 73.40; H, 5.52; N, 17.71 Found C, 73.37; H, 5.63; N, 17.69.

1-(2-Methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylpyridin-3-yl)-3-*p*-tolylurea (**38b**). White crystals from acetic acid yield 72%, m.p. 170–172 °C. FT-IR (KBr, cm<sup>-1</sup>): 3423 (NH); 2984, 2962, 2952 (CH); 1722 (CO); 1592 (C=C), <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.44 (s, 3H, CH<sub>3</sub>) 2.49 (s, 3H, CH<sub>3</sub>), 2.60 (s, 3H, CH<sub>3</sub>), 2.71 (s, 3H, CH<sub>3</sub>), 7.27–7.98 (m, 14H, ArH's and pyridine H-5), 8.90 (s, br, 2H, 2NH). Anal. Calcd. For C<sub>30</sub>H<sub>28</sub>N<sub>6</sub>O (488.60): C, 73.75; H, 5.17; N, 17.20 Found C, 73.80; H, 5.20; N, 17.30.

3-(2-Methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenyl-pyridin-3-yl)-quinazoline-2,4-(1*H*,3*H*)dione (**39**). White crystals from acetic acid, yield 65%, m.p. 190 °C. FT-IR (KBr, cm<sup>-1</sup>): 3424 (NH); 2983, 2926, 2875 (CH); 1722 (CO); 1594 (C=C). <sup>1</sup>H-NMR (300 MHz, DMSO-*d*<sub>6</sub>): δ = 2.43 (s, 3H, CH<sub>3</sub>), 2.50 (s, 3H, CH<sub>3</sub>), 2.59 (s, 3H, CH<sub>3</sub>), 7.44–7.97 (m, 14H, ArH's and pyridine H-5), 10.54 (s, br, 1H, NH), <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>) δ = 8.8, 20.5, 21.1, 114.2, 115.6, 117.2, 121.9, 123.7, 123.8, 128.5, 129.8, 132.7, 134.2, 134.6, 135.2, 137.8,

138.4, 138.7, 139.5, 140.2, 141.3, 144.2, 153.1, 158.6, 161.7, 164.6. Anal. Calcd. For  $C_{30}H_{24}N_6O_2$  (500.56): C, 71.99; H, 4.83; N, 16.79 Found C, 71.89; H, 4.79; N, 16.85.

### 3.1.17. Phenyl 2-Methyl-6-(5-methyl-1-(*p*-tolyl)-1*H*-1,2,3-triazol-4-yl)-4-phenylpyridin-3-yl)-carbamate (40)

A mixture of **34** (2 g, 5 mmol) and phenol (0.47 g, 5 mmol) in dry benzene (20 mL) was refluxed for 4 h. The resulting solid was collected and crystallized from ethanol, affording the corresponding **40**, as buff crystals, yield 70%, m.p. 140–142 °C. FT-IR (KBr,  $cm^{-1}$ ): 3425 (NH); 2984, 2925, 2866 (CH); 1722 (CO); 1597 (C=C).  $^1H$ -NMR (300 MHz, DMSO- $d_6$ ):  $\delta$  = 2.44 (s, 3H, CH<sub>3</sub>), 2.49 (s, 3H, CH<sub>3</sub>), 2.69 (s, 3H, CH<sub>3</sub>), 7.33–7.97 (m, 15H, ArH's and pyridine H-5), 11.65 (s, br, 1H, NH); Anal. Calcd. For  $C_{29}H_{25}N_5O_2$  (475.55): C, 73.25; H, 5.30; N, 14.73; Found C, 73.35; H, 5.40; N, 14.85.

## 4. Conclusions

Compound **1** proved to be useful for synthesis of a new series of novel functionalized 1,3,4-thiadiazoles, 1,3-thiazoles and pyridines containing 1,2,3-triazole moiety using hydrazonoyl halides as precursors. Also, compound **31** proved to be a useful precursor in the synthesis of various pyrazoles, urea and carbamate derivatives. The biological activities of the synthesized products will be reported in extended work.

**Acknowledgments:** The authors would like to thank the chemistry department, Faculty of Science, Cairo University for their financial support facilitating the publication of this study.

**Author Contributions:** A.O.A. and N.A.A. designed the research; A.O.A., N.A.A. and A.M.M.M. performed the research; A.O.A. and N.A.A. analyzed the data, wrote the paper and approved the final manuscript.

**Conflicts of Interest:** The authors declare that there is no conflict of interests regarding the publication of this paper.

## References

- Pericherla, K.; Khedar, P.; Khungar, B.M.; Kumar, A. Click chemistry inspired structural modification of azole antifungal agents to synthesize novel 'drug like' molecules. *Tetrahedron Lett.* **2012**, *53*, 6761–6764.
- Slamova, K.; Marhol, P.; Bezouska, K.; Lindkvist, L.; Hansen, S.; Kren, V.; Jensen, H. Synthesis and biological activity of glycosyl-1*H*-1,2,3-triazoles. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 4263–4265.
- Rao, P.S.; Kurumurthy, C.; Veeraswamy, B.; Kumar, G.S.; Poornachandra, Y. Synthesis of novel 1,2,3-triazole substituted-Nalkyl/aryl nitron derivatives, their anti-inflammatory and anticancer activity. *Eur. J. Med. Chem.* **2014**, *80*, 184–191.
- Jain, A.K.; Sharma, S.; Vaidya, A.; Ravichandran, V.; Agrawal, R.K. 1,3,4-Thiadiazole and its Derivatives: A Review on Recent Progress in Biological Activities. *Chem. Biol. Drug Des.* **2013**, *81*, 557–576.
- Altıntop, M.D.; Can, Ö.D.; Özkay, Ü.D.; Kaplançkl, Z.A. Synthesis and Evaluation of New 1,3,4-Thiadiazole Derivatives as Antinociceptive Agents. *Molecules* **2016**, *21*, 1004.
- Siddiqui, N.; Arshad, M.F.; Ahsan, W.; Alam, M.S. Thiazoles: A valuable insight into the recent advances and biological activities. *Int. J. Pharm. Sci. Drug Res.* **2009**, *1*, 136–143.
- Cardia, M.C.; Begala, M.; Delogu, A.; Maccioni, E.; Plumitallo, A. Synthesis and antimicrobial activity of novel arylideneisothiosemicarbazones. *IL Farmaco* **2000**, *55*, 93–95.
- Pandeya, S.N.; Sriram, D.; Nath, G.; Declercq, E. Synthesis, antibacterial, antifungal and anti HIV activities of schiff and mannich bases derived from isatin derivatives and *N*-[4-(4'-chlorophenyl) thiazol-2-yl] thiosemicarbazide. *Eur. J. Pharm. Sci.* **1999**, *9*, 25–31.
- Patrick, G.L.; Kinsmar, O.S. Synthesis and antifungal activity of novel azo-D-homosteroids, hydroisoquinolines, pyridines and hydropyridines. *Eur. J. Med. Chem. Chim. Ther.* **1996**, *31*, 615–624.
- Hishmat, O.H.; Abdel Galil, F.M.; Farrag, D.S. Synthesis and antimicrobial activity of new benzofuranylpipridine derivatives. *Pharmazie* **1990**, *45*, 793–795.
- Doshi, R.; Kagthara, P.; Parekh, H. Synthesis and biological evaluation of some novel isoxazoles and cyanopyridines, a new class of potential anti-tubercular agents. *Indian J. Chem.* **1999**, *38*, 348–352.

12. Le Manach, C.; Paquet, T.; Brunschwig, C.; Njoroge, M.; Han, Z.; Cabrera, D.G.; Bashyam, S.; Dhinakaran, R.; Taylor, D.; Reader, J.; et al. A Novel Pyrazolopyridine with in Vivo Activity in *Plasmodium berghei*- and *Plasmodium falciparum*-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines. *J. Med. Chem.* **2015**, *58*, 8713–8722.
13. Sadana, A.K.; Mirza, Y.; Aneja, K.R.; Prakash, O. Hypervalent iodine mediated synthesis of 1-aryl/heteryl-1,2,4-triazolo[4,3-*a*]pyridines and 1-aryl/heteryl 5-methyl-1,2,4-triazolo[4,3-*a*]quinolines as antibacterial agents. *Eur. J. Med. Chem.* **2003**, *38*, 533–536.
14. Datta, N.J.; Khunt, R.C.; Parikh, A.R. Aryl amides: Preparation and antimicrobial evaluation. *Inst. Chem. India* **2000**, *72*, 133–134.
15. Nagashree, S.; Mallesha, L.; Mallu, P. Synthesis and in vitro biological activity of 6-chloro-pyridin-2-yl-amine derivatives. *Der Pharma Chem.* **2013**, *5*, 50–55.
16. Pokhodylo, N.T.; Savak, R.D.; Matiichuk, V.S.; Obushak, N.D. Synthesis and selected transformation of 1-[4-(4-R-r-methyl-1-aryl-1H-1,2,3-triazol-1-yl)phenyl]ethanonees. *Russ. J. Gen. Chem.* **2009**, *79*, 309–314.
17. Klayman, D.L.; Bartosevich, J.F.; Griffin, T.S.; Mason, C.J.; Scovill, J.P. 2-Acetylpyridine thiosemicarbazones. 1. A new class of potential antimalarial agents. *J. Med. Chem.* **1979**, *22*, 855–862.
18. Bähr, G.; Schleitzer, G. Überemprotideschwermetall-innerkomplexe der A-diketondi-thiosemicarbazone (thiazone). IV. Untersuchungen zur konstitution. komplexe von thiazon-analogen. *Z. Anorg. Allg. Chem.* **1955**, *280*, 161–179.
19. Abdelhamid, A.O.; Zohdi, H.; Rateb, N. Reactions with hydrazonoyl halides part 21. Reinvestigation of the reactions of hydrazonoyl bromides with 1,1-dicyanothioacetanilide. *J. Chem. Res. Synop.* **1999**, *3*, 184–185.
20. Butler, R.N. *Comprehensive Heterocyclic Chemistry*; Katritzky, A.R., Rees, C.W., Scriven, E.F.V., Eds.; Pergamon Press: New York, NY, USA, 1996; Volume 4, pp. 621–678.
21. Huisgen, R.; Grashey, R.; Seidel, M.; Knupfer, H.; Schmidt, R. 1,3-Dipolare additionen, III. Umsetzungen des diphenylnitrilimins mit carbonyl und thiocarbonyl-verbindungen. *Justus Liebigs Chem.* **1962**, *658*, 169–180.
22. Ablajan, K.; Liju, W.; Tuoheti, A. An Efficient synthesis of some new hydrazone derivatives containing 1,2,3-triazole and thiazole. *Lett. Org. Chem.* **2013**, *10*, 715–721.
23. Yadav, R.C.; Sharma, P.K.; Singh, J. Synthesis and biological activity of 4''-substituted-2-(4'-formyl-3'-phenylpyrazole)-4-phenyl thiazole. *J. Chem. Pharm. Res.* **2013**, *5*, 78–84.
24. Dog, W.-J.; Cui, F.-H.; Gao, Z.-L.; Li, R.-S.; Shen, G.-L.; Dong, H.-S. An efficient synthesis of 5-aryl-4,5-dihydro-3-(5-methyl-1-*p*-tolyl-1H-1,2,3-triazol-4-yl)-1-(4-phenylthiazol-2-yl)-pyrazoles. *J. Heterocycl. Chem.* **2011**, *48*, 1154.
25. Dong, H.-S.; Wang, Y.-F.; Shen, G.-L.; Quan, B.; Dong, W.-J. Synthesis of some new 1-acyl-5-aryl-3-(5-methyl-1-*p*-tolyl-1H-1,2,3-triazol-4-yl)-4,5-dihydro-1H-pyrazole. *J. Heterocycl. Chem.* **2012**, *49*, 149.
26. Sharma, R.N.; Sharma, K.P.; Dixit, S.N. Synthesis, Characterization, and Biological activities of Some New Arylazopyrazoles. *Int. J. ChemTech Res.* **2010**, *2*, 800–806.
27. Studennikova, L.D. Hydrazones of acetacetic ester. *Sb. Nauch Ref. Zh. Kim.* **1969**, *1*, 71–73.
28. Shawali, A.S.; Osman, A. Synthesis and reactions of phenylcarbamoylarylhydrazidic chlorides. *Tetrahedron* **1971**, *27*, 2517–2528.
29. Shawali, A.S.; Abdelhamid, A.O. Reaction of dimethylphenacylsulfonium bromide with N-nitrosoacetaryl amides and reactions of the products with nucleophiles. *Bull. Chem. Soc. Jpn.* **1976**, *49*, 321–324.
30. Eweiss, N.F.; Osman, A. Synthesis of heterocycles. Part II. New routes to acetylthiadiazolines and alkylazothiazoles. *J. Heterocycl. Chem.* **1980**, *17*, 1713–1717.
31. Asiri, A.M.; Zayed, M.E.; Ng, S.W. Ethyl (Z)-2-chloro-2-(2-phenylhydrazin-1-ylidene)acetate. *Acta Crystallogr.* **2011**, *67*, o1962.

**Sample Availability:** Samples of the synthesized compounds are available from the authors.



© 2017 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<http://creativecommons.org/licenses/by/4.0/>).